NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,746.39 mln
Float67.12 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
46.09
Strong upside
Relative Strength
38
/ 100
Underperforming
Debt / Equity
0.01
Debt-free
ROE
-33.94
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Edgewise Therapeutics is a drug development company focused on treating serious muscle and heart conditions. Founded in 2017 and based in Boulder, Colorado, the company is advancing several experimental medicines, including sevasemten, an oral treatment for Duchenne and Becker muscular dystrophy currently in mid-stage clinical trials, alongside two early-stage heart medications targeting hypertrophic cardiomyopathy and heart failure. Its broader research effort centers on developing targeted treatments that work directly on the muscle proteins responsible for inherited muscle diseases.
